Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of BI 1291583 in Hepatic Impairment
NCT07023354Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of verducatib in bronchiectasis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 672 h and Maximum measured concentration of the analyte in plasma at Day 29. Started Jul 2025; status: recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT07023354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023354.